Baiyang Pharmaceutical: Zap Therapeutic intends to increase capital to Baiyang Sa Pu by $4.9 million to help ZAP-X Mars Boat Radiosurgery Robot quickly enter clinical settings.

Baiyang Pharmaceuticals announced that its wholly-owned subsidiary Baiyang Health Industry International Trading Co., Ltd.'s wholly-owned subsidiary Hebei Baiyang Sapp Medical Equipment Technology Co., Ltd. plans to introduce a capital increase of 4.9 million US dollars from Zap Therapeutic. After the capital increase, the registered capital of Baiyang Sapp will increase to 10 million US dollars, and Baiyang Health's shareholding ratio will decrease to 51%. In order to expand the company's product layout in the field of innovative medical devices, since July 2024, the company has successively made industrial investments in Zap Medical System, Ltd., and has carried out a series of exclusive commercial cooperation, manufacturing services, and other cooperation for its core product ZAP-X Marsboat Radiosurgery Robot. The capital increase from Zap Therapeutic to Baiyang Sapp can fully integrate the financial, technological, market channels, and other resources of both parties, and it is conducive to promoting the localization production of ZAP-X and facilitating the rapid introduction of ZAP-X into clinical scenarios.